Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,242 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Autism, Autism Spectrum Disorder
Interventions: MapHabit System (MHS); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: ACL, Opioid Use, Cryotherapy Effect, Vibration; Exposure, Pain, Postoperative
Interventions: VibraCool mechanical stimulation and neuromodulatory therapeutic device, Cryocompression (Game Ready, Bregs) device, Standard ice packs; Device
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Stem Cell Transplant Patients
Interventions: ACTivate sessions; Behavioral
Lead sponsor: Anthony Sung, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 476 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Kansas City, Kansas • Durham, North Carolina

Conditions: Inflammation, Depression Disorder, Mindfulness, Emotional Well-being, Physical Health, Mental Health
Interventions: Mindfulness-based cognitive therapy for perinatal depression, Pregnancy Health Group; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Interventions: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy; Biological · Drug
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
Interventions: Standard of Care + atorvastatin, Standard of Care (SOC); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HSV
Interventions: Benzoyl Peroxide 10% Bar, Placebo; Drug · Other
Lead sponsor: Greg Bew; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evans, Georgia

Conditions: Solid Tumor
Interventions: Larotrectinib, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Venous Leg Ulcer (VLU)
Interventions: Saline solution, Vashe solution; Device
Lead sponsor: Laboratoires URGO; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Leg Veins
Interventions: Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine, Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 20 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hydration, Dehydration (Physiology), Performance
Interventions: Water (Placebo), Carbohydrate Milk Permeate sports drink, 6% Sports drink, Low-Carbohydrate Milk Permeate sports drink; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions: RYZ711, PSMA PET/CT; Drug · Diagnostic Test
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Obesity & Overweight, Obese Adolescents, Metabolic Abnormalities
Interventions: Use of an unblinded CGM device; Device
Lead sponsor: University of Florida; Other
Eligibility: 13 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
Interventions: Not listed
Lead sponsor: Fibronostics USA, Inc; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Timeline: 2025
U.S. locations: 1
States / cities: Lady Lake, Florida

Conditions: C-Reactive Protein
Interventions: LY5625573, Midazolam, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • Dallas, Texas

Conditions: Human Papillomavirus-Related Cervical Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Weight Gain Trajectory, BMI, Responsive Parenting, Diet Quality, Implementation
Interventions: Data integration around responsive parenting, Standard Care (in control arm); Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Masticatory Myofascial Pain Syndrome
Interventions: Onabotulinumtoxin A, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Community Acquired Pneumonia (CAP)
Interventions: Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Burnie, Maryland • Towson, Maryland

Conditions: Cocaine Use Disorder (CUD)
Interventions: tFUS, Sham tFUS; Device
Lead sponsor: Mary Phillips, MD MD (Cantab); Other
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mantle Cell Lymphoma
Interventions: Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab, Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Patient Observation, Biospecimen Collection, Bone Marrow Aspiration; Drug · Biological · Procedure + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2038
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opioid Use Disorder
Interventions: ConCERN intervention, Treatment as Usual; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Breast Cancer, Breast Cancer Survivors
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Disease, Anesthesia, Post Operative Pain
Interventions: Lidocaine in Saline, Normal saline; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

Evaluating the Feasibility of Collecting User Interaction Data at the Emory Autism Center Using MapHabit Software

VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant Patients

Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias

The Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat

RYZ711 Diagnostic Platform Study

A Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention

Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

Evaluating Care Integration Between Pediatric Primary Care Providers and WIC Nutritionists

MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

Examination of Transcranial Focused Ultrasound on Brain Activity in Adults With Cocaine Use Disorder

Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial

The ConCERN Intervention for Loved Ones of Those With Opioid Use Disorder

Together-Breast Cancer Support Platform

Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds